Alterity Therapeutics Limited (ATHE)
| Market Cap | 26.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.52M |
| Shares Out | 41.18M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,304 |
| Open | 0.640 |
| Previous Close | 0.663 |
| Day's Range | 0.600 - 0.670 |
| 52-Week Range | 0.580 - 2.750 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ATHE
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limi...
News
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United ...
MELBOURNE, Australia , April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying trea...
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia and SAN FRANCISCO , April 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity...
Alterity Therapeutics to Present at the 34th Annual Roth Conference
MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing diseas...
Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease
Alterity Therapeutics's ATHE data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. [ALERT[ Matt Maley just released his latest pick with an upsi...
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinson...
MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatm...
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Highlights: NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to ...
Hot Penny Stocks to Watch Right Now That Are Moving in Premarket
These penny stocks climbed during premarket trading, here's why The post Hot Penny Stocks to Watch Right Now That Are Moving in Premarket appeared first on Penny Stocks to Buy, Picks, News and Informati...
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Al...
MELBOURNE, Australia and SAN FRANCISCO , Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing diseas...
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatme...
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
MELBOURNE, Australia, Dec. 14, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatm...
Alterity Therapeutics to Participate in Two Upcoming Investor Conferences
MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing diseas...
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021
MELBOURNE, Australia , Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatm...
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neuro...
MELBOURNE, Australia, Nov. 5, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatme...
Appendix 4C - Q1 FY22 Quarterly Cash Flow Report
Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress.
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Al...
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congre...
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise...
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases inc...
MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatme...
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report
Highlights: Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in...
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function
MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatm...
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Pa...
MELBOURNE, Australia and SAN FRANCISCO , July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition o...
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Highlights: Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence...
Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report
Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research evaluation Strengthening profile at investment, scientific and clinical conferences Dr David Stamler appoin...
Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerat...
Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. D...
Alterity to present at the 7th International Congress of Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International...
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commer...